Total Payments
$3,114
2023 Payments
$151.61
Companies
19
Transactions
183
Medicare Patients
795
Medicare Billing
$97,293
Payment Breakdown by Category
Food & Beverage$3,114 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,114 | 183 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $476.34 | 26 | $0 (2022) |
| Novo Nordisk Inc | $442.68 | 34 | $0 (2023) |
| AbbVie Inc. | $356.69 | 23 | $0 (2023) |
| Lilly USA, LLC | $239.65 | 12 | $0 (2022) |
| Esperion Therapeutics, Inc. | $204.61 | 16 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $191.01 | 9 | $0 (2023) |
| Horizon Therapeutics plc | $176.41 | 9 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $170.65 | 10 | $0 (2019) |
| GlaxoSmithKline, LLC. | $161.47 | 8 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $126.11 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $151.61 | 7 | Novo Nordisk Inc ($45.46) |
| 2022 | $593.30 | 35 | Novo Nordisk Inc ($119.45) |
| 2021 | $1,216 | 74 | AbbVie Inc. ($247.28) |
| 2020 | $813.32 | 46 | AstraZeneca Pharmaceuticals LP ($195.75) |
| 2019 | $142.58 | 9 | AstraZeneca Pharmaceuticals LP ($77.95) |
| 2018 | $147.59 | 9 | Supernus Pharmaceuticals, Inc. ($118.93) |
| 2017 | $49.82 | 3 | AstraZeneca Pharmaceuticals LP ($28.88) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/09/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Diabetes | ||||||
| 03/20/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 02/01/2023 | Kowa Pharmaceuticals America, Inc. | SEGLENTIS (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/28/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Diabetes | ||||||
| 01/24/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: NEUROSCIENCE | ||||||
| 01/05/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: Diabetes | ||||||
| 11/30/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/09/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: Diabetes | ||||||
| 10/28/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Diabetes | ||||||
| 10/04/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: RESPIRATORY | ||||||
| 09/30/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: NEUROSCIENCE | ||||||
| 09/21/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/10/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: Diabetes | ||||||
| 07/27/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: Respiratory | ||||||
| 07/26/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Diabetes | ||||||
| 07/06/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: DIABETES | ||||||
| 07/06/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/01/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: Diabetes | ||||||
| 07/01/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $1.22 | General |
| Category: Diabetes | ||||||
| 06/27/2022 | Lilly USA, LLC | EMGALITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $26.08 | General |
| Category: Neuroscience | ||||||
| 06/09/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/06/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 134 | 247 | $43,994 | $18,673 |
| 2022 | 4 | 173 | 324 | $55,663 | $23,919 |
| 2021 | 7 | 243 | 398 | $58,032 | $27,947 |
| 2020 | 7 | 245 | 449 | $62,581 | $26,754 |
Total Patients
795
Total Services
1,418
Medicare Billing
$97,293
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 122 | $19,154 | $7,613 | 39.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 34 | 80 | $12,560 | $5,325 | 42.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 29 | 29 | $9,048 | $4,199 | 46.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 16 | $3,232 | $1,537 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 85 | 179 | $28,103 | $11,435 | 40.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 49 | 102 | $16,014 | $6,736 | 42.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 26 | 26 | $8,112 | $3,784 | 46.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 17 | $3,434 | $1,964 | 57.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 84 | 184 | $27,054 | $12,367 | 45.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 39 | 39 | $11,300 | $5,871 | 52.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 33 | 60 | $8,972 | $4,454 | 49.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 19 | 27 | $5,256 | $2,937 | 55.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 21 | $3,990 | $2,093 | 52.5% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2021 | 28 | 36 | $694.00 | $118.08 | 17.0% |
| 81002 | Urinalysis, manual test | Office | 2021 | 24 | 31 | $766.00 | $107.88 | 14.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 83 | 244 | $34,163 | $14,161 | 41.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 42 | 42 | $11,682 | $5,610 | 48.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 37 | 51 | $7,140 | $3,159 | 44.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 20 | $3,600 | $1,824 | 50.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 15 | $4,500 | $1,745 | 38.8% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2020 | 33 | 51 | $918.00 | $165.81 | 18.1% |
| 81002 | Urinalysis, manual test | Office | 2020 | 21 | 26 | $578.00 | $89.24 | 15.4% |
About Dr. Alberto Borges, M.D
Dr. Alberto Borges, M.D is a Hematology & Oncology healthcare provider based in Oakton, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1962531418.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alberto Borges, M.D has received a total of $3,114 in payments from pharmaceutical and medical device companies, with $151.61 received in 2023. These payments were reported across 183 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,114).
As a Medicare-enrolled provider, Borges has provided services to 795 Medicare beneficiaries, totaling 1,418 services with total Medicare billing of $97,293. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oakton, VA
- Active Since 03/02/2007
- Last Updated 03/21/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1962531418
Products in Payments
- FARXIGA (Drug) $401.05
- VRAYLAR (Drug) $347.28
- Ozempic (Drug) $315.64
- NEXLETOL (Drug) $204.61
- XARELTO (Drug) $191.01
- TROKENDI XR (Drug) $170.65
- TRELEGY ELLIPTA (Drug) $126.45
- TRULICITY (Drug) $121.77
- JARDIANCE (Drug) $110.13
- EMGALITY (Drug) $103.42
- RAYOS (Drug) $94.14
- Vascepa (Drug) $85.68
- PENNSAID (Drug) $82.27
- UBRELVY (Drug) $80.36
- Rybelsus (Drug) $80.16
- BREZTRI (Drug) $75.29
- Movantik (Drug) $60.39
- JANUVIA (Drug) $58.99
- COLOGUARD DNA CAPTURE REAGENTS (Device) $57.14
- NURTEC ODT (Drug) $51.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.